Genomic sequencing of key genes in mouse pancreatic cancer cells

Current Molecular Medicine

Volumn 12, Issue 3, 2012, Pages 331-341

  Wang, Y ^a,b   Zhang, Y ^c   Yang, J ^b   Ni, X ^b   Liu, S ^c   Li, Z ^a   Hodges, S E ^c   Fisher, W E ^c   Brunicardi, F C ^c,d   Gibbs, R A ^e   Gingras, M C ^e   Li, M ^b,c  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

CDKN2A (p16); Genomic sequence; KRAS; Mouse pancreatic cancer; PDX 1; SMAD4; TP53(p53); ZIP4

Indexed keywords

DNA; K RAS PROTEIN; PROTEIN P16; PROTEIN P53; SMAD4 PROTEIN; TRANSCRIPTION FACTOR PDX 1;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CODON; CONTROLLED STUDY; GENE MUTATION; GENE SEQUENCE; GENOMICS; HOMOZYGOTE; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PHENOTYPE; RNA TRANSLATION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HOMEODOMAIN PROTEINS; MICE; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS P21(RAS); SEQUENCE ANALYSIS, DNA; SMAD4 PROTEIN; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863124966     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652412799218868     Document Type: Article

References (40)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009; 6: 412-422.
3. Yonezawa S, Higashi M, Yamada N, Goto M. Precursor lesions of pancreatic cancer. Gut Liver 2008; 2: 137-154.
4. Li M, Zhang Y, Liu Z, et al. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc Natl Acad Sci USA 2007; 104: 18636-18641.
5. Li M, Zhang Y, Bharadwaj U, et al. Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin Cancer Res 2009; 15: 5993-6001.
6. Liu SH, Patel S, Gingras MC, et al. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer 2011; 117: 723-733.
7. Wang B, Shi Q, Abbruzzese J, Xiong Q, Le X, Xie K. A novel, clinically relevant animal model of metastatic pancreaticadenocarcinoma biology and therapy. Int J Gastrointest Cancer 2001; 29: 37-46.
8. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res 1984; 44: 717-726.
9. Voidonikolas G, Kreml SS, Chen C, et al. Basic principles and technologies for deciphering the genetic map of cancer. World J Surg 2009; 33: 615-629.
10. Mu DQ, Peng YS, Xu QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol 2004; 10: 471-475.
11. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009; 15: 4674-4679.
12. Schutte M, Hruban RH, Hedrick L, et al. DPC4 gene in various tumor types. Cancer Res 1996; 56: 2527-2530.
13. Smith-Sorensen B, Hovig E. CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 1996; 7: 294-303.
14. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011; 223: 116-126.
15. Kury S, Kharfi M, Kamoun R, et al. Mutation spectrum of human SLC39A4 in a panel of patients with acrodermatitis enteropathica. Hum Mutat 2003; 22: 337-338.
16. Wang K, Zhou B, Kuo YM, Zemansky J, Gitschier J. A novel member of a zinc transporter family is defective in acrodermatitis enteropathica. Am J Hum Genet 2002; 71: 66-73.
17. Macfarlane WM, Frayling TM, Ellard S, et al. Missense mutations in the insulin promoter factor-1 gene predispose to type 2 diabetes. J Clin Invest 1999; 104: R33-R39.
18. Hani EH, Stoffers DA, Chevre JC, et al. Defective mutations in the insulin promoter factor-1 (IPF-1) gene in late-onset type 2 diabetes mellitus. J Clin Invest 1999; 104: R41-R48.
19. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
20. Moore PS, Sipos B, Orlandini S, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001; 439: 798-802.
21. Garrett CR, Eng C. Cetuximab in the treatment of patients with colorectal cancer. Expert Opin Biol Ther 2011; 11: 937-949.
22. Ryozawa S, Iwano H, Taba K, Sen-yo M, Uekitani T. Genetic diagnosis of pancreatic cancer using specimens obtained by EUS-FNA. Dig Endosc 2011; 23: 43-45.
23. Morris JP, Wang SC Hebrok M. KRAS, Hedgehog, Wint and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683-695.
24. Brune K, Hong SM, Li A, et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev 2008; 17: 3536-3542.
25. Wistuba, II, Behrens C, Albores-Saavedra J, Delgado R, Lopez F, Gazdar AF. Distinct K-ras mutation pattern characterizes signet ring cell colorectal carcinoma. Clin Cancer Res 2003; 9: 3615-3619.
26. Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21: 659-693.
27. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998; 95: 737-740.
28. Wrighton KH, Lin X, Feng XH. Phospho-control of TGF-beta superfamily signaling. Cell Res 2009; 19: 8-20.
29. Miyaki M, Kuroki T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem Biophys Res Commun 2003; 306: 799-804.
30. Yeh KT, Chen TH, Yang HW, et al. Aberrant TGFbeta/SMAD4 signaling contributes to epigeneticsilencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics 2011; 6: 727-739.
31. Geraldo MV, Yamashita AS, Kimura ET. MicroRNA miR- 146b-5p regulates signal transduction of TGF-beta by repressing SMAD4 in thyroid cancer. Oncogene 2011; [Epub ahead of print]
32. Derynck R, Zhang YE. Smad-dependent and Smadindependent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
33. Kuang C, Chen Y. Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction. Oncogene 2004; 23: 1021-1029.
34. Robertson KD, Jones PA. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene 1999; 18: 3810-3820.
35. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
36. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet 2011; 19: 472-478.
37. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033.
38. Sharma S, Jhala US, Johnson T, Ferreri K, Leonard J, Montminy M. Hormonal regulation of an islet-specific enhancer in the pancreatic homeobox gene STF-1. Mol Cell Biol 1997; 17: 2598-2604.
39. Schwitzgebel VM, Mamin A, Brun T, et al. Agenesis of human pancreas due to decreased half-life of insulin promoter factor 1. J Clin Endocrinol Metab 2003; 88: 4398-4406.
40. Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int 2011; 2011: 620601 (article ID).